

CORRECTION



Correction to: Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients

Michelle J. M. Janssen , Anke H. W. Bruns, Frans M. Verduyn Lunel, Reinier A. P. Raijmakers, Roel J. de Weijer, Nening M. Nanlohy, Gaby P. Smits, Debbie van Baarle and Jürgen Kuball

© The Author(s), under exclusive licence to Springer Nature Limited 2022

Bone Marrow Transplantation (2022) 57:1050; https://doi.org/10.1038/s41409-022-01651-4

Correction to: *Bone Marrow Transplant* https://doi.org/10.1038/s41409-021-01437-0, published online 20 August 2021

In Table 2 the outlining has been done incorrectly, as now the "univariate analysis" has been put above "p value", and "multivariate analysis" has been put above both the univariate and multivariate results.

Furthermore, another error had occurred in Table 2, namely instead of <135/170 (cell counts), in this table it says ">", which is incorrect, it should be read "<".

The correct Table 2 is given below.

The original article has been corrected.

Table 2	Univariate and	multivariate	analysis fo	r vaccine failure.
iable 2.	Univariate and	munivariate	anaivsis io	i vaccine ialiure.

	Student's t test		Univariate analysis		Multivariate analysis	
Parameter	Mean difference (±SD)	P	OR (95% CI)	P	OR (95% CI)	P
aGVHD grade ≥II within 3 months prior to vaccination			9.00 (0.89–90.84)	0.06		
Infections during follow-up						
Respiratory viruses			2.84 (1.01-7.98)	0.04		
Viral reactivations during follow-up			3.34 (1.13-9.86)	0.02	6.53 (1.22-34.95)	0.03
Epstein-Barr virus			2.68 (1.06-6.82)	0.04		
Total number of infections and reactivations	-0.85 (±0.43)	0.05				
Total of infections and reactivations >4			3.20 (0.93-11.04)	0.08		
Usage of relevant immunosuppressive drugs						
Steroids			4.74 (1.46–15.44)	0.01		
Rituximab			14.39 (0.67–310.25)	0.09		
Cell counts at first vaccination						
B-cells <135 per mm ³	180.23 (±64.68)	0.01	11.33 (3.64–35.34)	0.00	7.24 (1.89–27.68)	0.00
NK-cells <170 per mm ³	120.49 (±42.88)	0.01	7.89 (2.65–23.53)	0.00	11.06 (2.39–51.07)	0.00

Parameters investigated in univariate analysis included patient characteristics (age at hematopoietic stem cell transplantation (HSCT), sex, hematological diagnosis), data on HSCT (donor type, cell source, conditioning, anti-thymocyte globuline (ATG), total body irradiation (TBI), T-cell depletion), data on follow-up period (acute graft-versus-host disease (aGVHD), infections and reactivations, usage of relevant immunosuppressive drugs), data on vaccination (time between HSCT and first vaccination, cell counts at the moment of vaccination). P < 0.10 in univariate analysis were included in multivariate logistic regression analysis. Hosmer and Lemeshow test P = 0.966 for this multivariate model. *This OR was calculated by using the Haldane-Anscombe correction.

Published online: 31 March 2022